Articles In Press
Back to the articles list |
Back to browse issues page
1- Department of Traditional Persian Medicine, Golestan University of Medical Sciences, Gorgan, Iran
2- Asistant Professor of Epidemiology, Department of Bistatistitics and Epidemiology, School of Health, Golestan University of Medical Siences
3- Student in Persian Medicine,Department of Traditional Persian Medicine, Golestan University of Medical Sciences, Gorgan, Iran.(
4- d- Neyshabur University of Medical Sciences, Neyshabur, Iran ,Dr.sepehrikia@yahoo.com
2- Asistant Professor of Epidemiology, Department of Bistatistitics and Epidemiology, School of Health, Golestan University of Medical Siences
3- Student in Persian Medicine,Department of Traditional Persian Medicine, Golestan University of Medical Sciences, Gorgan, Iran.(
4- d- Neyshabur University of Medical Sciences, Neyshabur, Iran ,
Abstract: (6 Views)
Background and Objectives: This randomized, double-blind, placebo-controlled clinical trial investigates the efficacy of Taryaqe Vabaei, a traditional herbal formulation consisting of Aloe barbadensis, Commiphora myrrh, and Crocus sativus, in alleviating Upper respiratory tract infections (URTIs) symptoms.
Materials and methods: Sixty-six participants aged 25–60 with mild URTI symptoms were randomized into two groups. The intervention group received 500 mg of Taryaqe Vabaei twice daily for 14 days, while the control group received a placebo. Symptom severity was the primary outcome. For normally distributed data, independent and paired t-tests were used; for non-normally distributed data, the Mann-Whitney U and Wilcoxon signed-rank tests were applied. Categorical variables were analyzed using the chi-square test (SPSS v.26, significance at P<0.05).
Results: The intervention group showed significantly faster recovery times for body pain (0.85±1.23 vs. 4.36±1.82 days, p<0.001), sore throat (p<0.001), runny nose (p<0.001), cough (p<0.001), sneezing (p<0.001), fever (p<0.001), and confusion (0.71±1.43 vs. 0.06±0.36 days, p=0.01). Symptom severity decreased by 40% after one week in the intervention group, with significant improvements in overall symptom scores compared to placebo.
Conclusion: Although Taryaqe Vabaei showed promising results in reducing URTI symptoms, larger, longer-term studies are required to confirm its efficacy, explore safety profiles, and assess potential interactions with conventional treatments. These findings highlight the potential of Taryaqe Vabaei as an effective complementary therapy for managing URTIs.
Materials and methods: Sixty-six participants aged 25–60 with mild URTI symptoms were randomized into two groups. The intervention group received 500 mg of Taryaqe Vabaei twice daily for 14 days, while the control group received a placebo. Symptom severity was the primary outcome. For normally distributed data, independent and paired t-tests were used; for non-normally distributed data, the Mann-Whitney U and Wilcoxon signed-rank tests were applied. Categorical variables were analyzed using the chi-square test (SPSS v.26, significance at P<0.05).
Results: The intervention group showed significantly faster recovery times for body pain (0.85±1.23 vs. 4.36±1.82 days, p<0.001), sore throat (p<0.001), runny nose (p<0.001), cough (p<0.001), sneezing (p<0.001), fever (p<0.001), and confusion (0.71±1.43 vs. 0.06±0.36 days, p=0.01). Symptom severity decreased by 40% after one week in the intervention group, with significant improvements in overall symptom scores compared to placebo.
Conclusion: Although Taryaqe Vabaei showed promising results in reducing URTI symptoms, larger, longer-term studies are required to confirm its efficacy, explore safety profiles, and assess potential interactions with conventional treatments. These findings highlight the potential of Taryaqe Vabaei as an effective complementary therapy for managing URTIs.
Keywords: Aloe barbadensis, Commiphora myrrh, Crocus sativus, Persian Medicine, Complementary Medicine, Respiratory Tract Infections.medicine
Type of Study: Clinical Trials |
Subject:
Clinical Medicine
Received: 2025/05/16 | Accepted: 2026/06/22
Received: 2025/05/16 | Accepted: 2026/06/22
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |